Hancock Whitney Corp Sells 1,928 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Hancock Whitney Corp cut its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 4.7% in the 3rd quarter, Holdings Channel reports. The firm owned 38,928 shares of the biopharmaceutical company’s stock after selling 1,928 shares during the period. Hancock Whitney Corp’s holdings in Catalyst Pharmaceuticals were worth $774,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Arizona State Retirement System raised its position in shares of Catalyst Pharmaceuticals by 2.2% in the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock worth $461,000 after acquiring an additional 654 shares in the last quarter. GAMMA Investing LLC grew its stake in Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares during the period. XTX Topco Ltd raised its holdings in Catalyst Pharmaceuticals by 7.5% in the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 773 shares in the last quarter. Strategic Advocates LLC lifted its position in Catalyst Pharmaceuticals by 6.5% during the second quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 864 shares during the period. Finally, Sei Investments Co. lifted its position in Catalyst Pharmaceuticals by 1.3% during the second quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company’s stock valued at $1,308,000 after buying an additional 1,098 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Citigroup raised their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Truist Financial boosted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Stephens initiated coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Trading Up 3.5 %

Shares of CPRX opened at $21.93 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.00 and a 12 month high of $24.27. The business’s fifty day simple moving average is $21.14 and its two-hundred day simple moving average is $18.62. The company has a market cap of $2.62 billion, a price-to-earnings ratio of 18.58, a P/E/G ratio of 3.31 and a beta of 0.75.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.